Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate to severe psoriasis: Results from the randomized treatment withdrawal phase of a phase 3, randomized, controlled trial (ESTEEM 1)

被引：0
|
作者：
Papp, Kim [1 ]
Griffiths, Christopher [2 ]
Leonardi, Craig [3 ]
Reich, Kristian [4 ,5 ]
Kircik, Leon [6 ]
Day, Robert [7 ]
Chimenti, Sergio [8 ]
机构：
[1] Prob Med Res, Windsor, ON, Canada
[2] Univ Manchester, Dermatol Ctr, Manchester, Lancs, England
[3] St Louis Univ, Sch Med, St Louis, MO USA
[4] SCIderm Res Inst, Hamburg, Germany
[5] Dermatol Hamburg, Hamburg, Germany
[6] Phys Skin Care PLLC, Louisville, KY USA
[7] Celgene Corp, Warren, NJ USA
[8] Univ Roma Tor Vergata, Rome, Italy
来源：
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY | 2014年 / 70卷 / 05期
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
P8359
引用
收藏
页码：AB164 / AB164
页数：1
相关论文
共 50 条
  • [1] Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate to severe psoriasis: ESTEEM 1 randomized treatment withdrawal phase results
    Foley, P.
    Papp, K.
    Reich, K.
    Leonardi, C.
    Kircik, L.
    Chimenti, S.
    Hu, C. C.
    Stevens, R. M.
    Day, R. M.
    Griffiths, C. E. M.
    [J]. AUSTRALASIAN JOURNAL OF DERMATOLOGY, 2014, 55 : 35 - 35
  • [2] Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate to severe psoriasis: 16-week results of a phase III, randomized, controlled trial (esteem 1)
    Reich, K.
    Papp, K.
    Leonardi, C.
    Kircik, L.
    Chimenti, S.
    Hu, C.
    Stevens, R.
    Day, R. M.
    Griffiths, C. E.
    [J]. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2013, 27 : 22 - 23
  • [3] Two-year safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate to severe plaque psoriasis: Results from a phase 3, randomized, controlled trial (ESTEEM 1)
    Papp, Kim A.
    Reich, Kristian
    Sobell, Jeffrey M.
    Menter, Alan
    Lacour, Jean-Philippe
    Chimenti, Sergio
    Hu, ChiaChi
    Day, Robert M.
    Shah, Kamal
    Griffiths, Christopher E. M.
    [J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2015, 72 (05) : AB256 - AB256
  • [4] Apremilast in patients with moderate to severe psoriasis: Results of a phase 3, randomized, controlled trial (ESTEEM 2)
    Mrowietz, U.
    Paul, C.
    Gooderham, M.
    Cather, J.
    Poulin, Y.
    Girolomoni, G.
    Ferrandiz, C.
    Gottlieb, A.
    Hu, C. C.
    Day, R.
    Crowley, J.
    [J]. JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2015, 13 : 93 - 94
  • [5] Long-term safety and tolerability of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate to severe psoriasis: Results from a phase III, randomized, controlled trial (ESTEEM 1)
    Reich, Kristian
    Griffiths, Christopher
    Leonardi, Craig
    Papp, Kim
    Kircik, Leon
    Day, Robert
    Chimenti, Sergio
    [J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2014, 70 (05) : AB174 - AB174
  • [6] Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1)
    Papp, Kim
    Reich, Kristian
    Leonardi, Craig L.
    Kircik, Leon
    Chimenti, Sergio
    Langley, Richard G. B.
    Hu, ChiaChi
    Stevens, Randall M.
    Day, Robert M.
    Gordon, Kenneth B.
    Korman, Neil J.
    Griffiths, Christopher E. M.
    [J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2015, 73 (01) : 37 - 49
  • [7] Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis: results of a phase 3, randomized, controlled trial
    Kavanaugh, Arthur
    Mease, Philip J.
    Gomez-Reino, Juan J.
    Adewale, Adebajo
    Wollenhaupt, Juergen
    Hu, ChiaChi
    Stevens, Randall
    Cutolo, Maurizio
    [J]. CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2013, 31 (05) : 832 - 832
  • [8] Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis: results of a phase 3, randomized, controlled trial (palace 1)
    Adebajo, A. O.
    Kavanaugh, A.
    Mease, P. J.
    Gomez-Reino, J. J.
    Wollenhaupt, J.
    Hu, C.
    Stevens, R.
    [J]. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2013, 27 : 53 - 54
  • [9] Apremilast, an oral phosphodiesterase 4 inhibitor, in the treatment of Japanese patients with moderate to severe plaque psoriasis: Efficacy, safety and tolerability results from a phase 2b randomized controlled trial
    Ohtsuki, Mamitaro
    Okubo, Yukari
    Komine, Mayumi
    Imafuku, Shinichi
    Day, Robert M.
    Chen, Peng
    Petric, Rosemary
    Maroli, Allan
    Nemoto, Osamu
    [J]. JOURNAL OF DERMATOLOGY, 2017, 44 (08): : 873 - 884
  • [10] Apremilast, an Oral Phosphodiesterase 4 Inhibitor, in Patients with Psoriatic Arthritis: Results of a Phase 3, Randomized, Controlled Trial (PALACE 1)
    Adebajo, A. O.
    Kavanaugh, A.
    Mease, P. J.
    Gomez-Reino, J. J.
    Wollenhaupt, J.
    Hu, C.
    Stevens, R.
    [J]. CLINICAL RHEUMATOLOGY, 2013, 32 : S123 - S123
12345